FDA Approves Otsuka’s SIMTRIYO as First-in-Class NDSRI for ADHD

The U.S. Food and Drug Administration has granted approval to Otsuka Pharmaceutical for SIMTRIYO (centanafadine), marking the first regulatory clearance for a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) intended for the treatment of attention-deficit/hyperactivity disorder (ADHD).

Indicated for pediatric patients aged 6 years and older weighing at least 20kg, as well as adult patients, the medication is formulated as a once-daily, extended-release capsule.

Key Regulatory Proposals

The approval of SIMTRIYO is underpinned by data from four pivotal Phase 3 clinical trials, which utilized the ADHD Rating Scale-5 for pediatric cohorts and the Adult ADHD Investigator Symptom Rating Scale for adults.

Results indicated statistically significant improvements in ADHD symptom management, with efficacy observed as early as the first week of treatment.

Safety profiles were established across all studied age groups. Common adverse reactions in pediatric and adolescent populations included headache, nausea, rash, decreased appetite, and abdominal pain. Adult patients reported similar side effects, with the addition of insomnia, dry mouth, and diarrhea. Otsuka is also evaluating the therapeutic utility of the drug for patients with comorbid anxiety, as evidenced by a recent Phase 3b study; comprehensive findings from this trial are slated for presentation at a future scientific forum.

The drug is expected to launch commercially in the United States later this year, contingent upon final scheduling determinations by the Drug Enforcement Administration (DEA).

Industry Context

ADHD currently impacts an estimated 22.5 million individuals in the United States, a population comprised of 7 million children and 15.5 million adults. Characterized by persistent impulsivity, hyperactivity, and attention deficits, the disorder represents a substantial public health burden.

The launch of SIMTRIYO signifies a technical evolution within the neuro-psychiatric sector, shifting the paradigm from traditional mono- or dual-reuptake inhibitors toward more complex, multi-transmitter modulation. This transition highlights a broader industry trend toward personalized, precision-based medicine for psychiatric conditions.

As the pharmaceutical landscape moves toward more nuanced therapeutic options, stakeholders anticipate increased scrutiny from payers regarding the cost-benefit analysis and comparative efficacy of this new agent against existing standard-of-care treatments.